Printer Friendly

Calypte Receives Initial Order for the Middle East; Additional Orders Expected as Regulatory Approvals Received.

Business Editors/Health/Medical Writers

ALAMEDA, Calif.--(BUSINESS WIRE)--June 24, 2003

Calypte Biomedical Corporation (OTCBB:CYPT), the developer and marketer of the only two FDA approved HIV-1 antibody tests for use with urine samples, announced that it has received an initial order from Mistaire LLC for HIV-1 Urine EIA screening tests and Urine HIV-1 Western Blot supplemental tests for use within the United Arab Emirates (UAE). Calypte recently sent representatives to the UAE to undertake demonstrations and training sessions.

In April, Calypte announced its appointment of Mistaire as its exclusive distribution for the six member states of the Gulf Cooperative Council (GCC), which include Saudi Arabia, UAE, Bahrain, Qatar, Kuwait, and Oman. Additional orders from other GCC states are anticipated as the urine HIV tests gain regulatory clearances.

"We had not been forecasting sales from this region until later in the year, and we are certainly pleased with the quick action and initiative shown by Mistaire," said Tony Cataldo, Calypte's Executive Chairman. "This early success suggests that the benefits of our painless and safer testing option should become readily available throughout the GCC in the foreseeable future."

B.J. Harid, President of Mistaire, stated, "When we took on the Calypte urine HIV tests, we did so in the belief that the potential safety hazards associated with traditional blood tests are a significant concern even in this region where the incidence of AIDS is relatively low, and that urine testing could make a meaningful contribution to improving the safety of HIV testing for all parties concerned. Our early findings support that premise, and we will be actively working to maximize the opportunity."

"The GCC market is an interesting one for us, because it shows that the benefits of urine HIV testing over traditional blood-based approaches apply equally in low-prevalence settings as they do in those regions hardest hit by the epidemic," said Richard VanMaanen, Calypte's Director of International Business Development.

About Mistaire LLC

Mistaire LLC is a U.S.-based corporation headquartered in New York City. Mistaire Ltd., an associated company in India, operates a manufacturing facility for biochemistry reagents and pharmaceutical products, and distributes those products in both India and the GCC. Mistaire's GCC operations are headquartered in Dubai, United Arab Emirates.

About Calypte Biomedical

Calypte Biomedical Corporation, headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. When compared with existing blood-based tests, our testing algorithms are non-invasive, easier to use, less expensive and have significantly less risk than blood-based testing, and they have 99.7% sensitivity in subjects previously identified as HIV-1 infected and 100% specificity in subjects at low risk when combined with the urine-based Western Blot supplemental test(a). The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners.

(a) "The performance of testing urine samples for HIV-1 antibodies is reduced in some populations in comparison to testing blood. Please refer to the product inserts for details."

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing and access funds from our existing financing arrangements that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K for the year ended December 31, 2002, and its subsequent filings with the SEC.
COPYRIGHT 2003 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion




Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:7UNIT
Date:Jun 24, 2003
Previous Article:MtM Information Technologies Ranked among North America's Top 500 Technology Integrators by CMP's VARbusiness Magazine.
Next Article:Offshore Systems, Kelvin Hughes and Lockheed Martin UK Form Alliance to Pursue Warship Navigation Systems Market.

Related Articles
Urine HIV-1 Test To be Distributed in 13 Additional Foreign Countries; Calypte Biomedical Selects Four New Distributors.
Calypte Reports Third Quarter Results.
FDA Approves Conversion of Calypte Urine Western Blot BLA to Premarket Approval Status.
Calypte Reports Third Quarter 2001 Financial Results; Revenues Increase 75% Compared With Third Quarter 2000.
Calypte Receives First Commercial Order in China With New Distributor; Order for 100,000 Tests to Ship in Fourth Quarter 2002.
Calypte Announces Third Quarter and Nine-Month Financial Results; Management Expects Sequential Fourth Quarter Revenue Growth of at Least 50 to 75%.
Calypte Receives Second Commercial Order from China Distributor and Payment for First Order; New Order for 160,000 Tests to Ship in February 2003.
Calypte Receives Exemption from FDA Lot Release Testing; Production-to-Market Time for HIV-1 Urine EIA Test Significantly Reduced.
Calypte Expands Distribution into the Middle East; Mistaire LLC Selected to Distribute Calypte Products Throughout the GCC.

Terms of use | Copyright © 2015 Farlex, Inc. | Feedback | For webmasters